Home / Letter From The Editor / Nov. 24, 2018

Nov. 24, 2018

Nov 24, 2018

Over the last 25 years, we have been looking for add-on therapies to help our type 1 patients control their glucose without increasing the risk of hypoglycemia. As we have gotten better insulins and monitoring devices, there has been an intensification of control and that often leads to greater changes of low glucose. We have tried to find ways to improve control without increasing the risk of hypoglycemia. Years ago, clinicians tried to add a TZD, thinking that the increased insulin sensitivity would lead to better values, and then we had the amylin analog, that seemed to work but added 2 to 3 more injections a day. Lately, we have tried adding either a GLP-1 or an SGLT-2 inhibitor hoping to decrease glucose uptake, with some success.

The holy grail of treatments could be a drug that increases the uptake of glucose into the cells independent of insulin or insulin sensitizers. This week, our Pharm. D. Candidate from LECOM School of Pharmacy, Michael Zaccaro, brings us information on the polyclonal antibody mixture, Subetta, which is in Phase 3 clinical trials and works by a totally different mechanism. This could be the first in a new class of drugs that makes increased control possible.



We can make a difference!


Dave Joffe